Breaking Update: Here’s a clear explanation of the latest developments related to Breaking News:Novel Nanoparticle Therapy for Allergic Rhinitis – EMJ– What Just Happened and why it matters right now.
ALLERGIC rhinitis may soon be treated at its source rather than just its symptoms, as new research unveiled a nanoparticle-based nasal therapy designed to rebalance the immune system.
With hayfever season approaching, millions of individuals are preparing for the familiar burden of sneezing, congestion, and itchy eyes. Allergic rhinitis, driven by immunoglobulin E (IgE)-mediated responses, remains one of the most common chronic respiratory conditions worldwide, yet current treatments largely focus on symptom control rather than addressing underlying immune dysfunction.
In a new preclinical study, researchers investigated whether intranasal delivery of bryostatin-1 (bryo-1) using surface charge-engineered lipid nanoparticles (LNPs) could offer a more targeted and disease-modifying approach.
Allergic Rhinitis Treatment Targets Immune Imbalance
Bryo-1, a compound known to inhibit IgE-mediated allergic responses, has shown promise in modulating immune activity. However, its clinical use has been limited by poor stability, high cost, and difficulty penetrating the nasal mucosal barrier.
To overcome these challenges, the researchers developed LNPs with varying surface charges to improve delivery. In laboratory experiments, these engineered nanoparticles demonstrated enhanced uptake by antigen-presenting cells, improving the efficiency of bryo-1 delivery.
Notably, anionic LNPs showed superior targeting of B cells, promoting immunoglobulin A (IgA) production while suppressing IgE expression. This shift is significant, as IgA plays a key role in mucosal defence, helping to protect the nasal lining from allergens.
Intranasal Nanoparticles Boost Mucosal Defence
In a mouse model of allergic rhinitis, even a very low dose (0.5 ng) of bryo-1 delivered via anionic LNPs increased antigen-specific IgA levels in salivary secretions. These findings suggest that the approach not only reduces allergic responses but may also strengthen the body’s natural mucosal immunity.
Importantly, this strategy represents a move towards causal treatment, aiming to correct immune imbalance rather than simply alleviating symptoms. However, the findings remain limited to preclinical models, and further studies will be required to confirm safety, optimal dosing, and effectiveness in humans.
If translated successfully into clinical practice, this approach could mark a significant shift in how allergic rhinitis is managed, particularly during peak allergy seasons when the burden on patients and healthcare systems is highest.
Reference
Li J et al. Intranasal delivery of bryostatin-1 using surface charge-engineered lipid nanoparticles to modulate mucosal defense for allergic rhinitis treatment. Sci Rep. 2026;DOI:10.1038/s41598-026-43174-8.
Featured image: Anastasiya on Adobe Stock